Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages 5097-5100

  Niitsu, Nozomi ^a   Hagiwara, Yuki ^a   Tanae, Ken ^a   Kohri, Mika ^a   Takahashi, Naoki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SEX DIFFERENCE; TREATMENT OUTCOME; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DNA, VIRAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDNISONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; VINCRISTINE; VIRUS ACTIVATION;

EID: 78650064032     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.7531     Document Type: Article

References (8)

1. Kusumoto S, Tanaka Y, Mizokami M, et al: Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23, 2009
2. Yeo W, Chan TC, Leung NW, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitisBundergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009
3. Pei SN, Chen CH, Lee CM, et al: Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255-262, 2010
4. Niitsu N, Kohri M, Hagiwara Y, et al: Multicenter phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. Hematol Oncol 28:68-74, 2010
5. Goedel S, Rullkoetter M, Weisshaar S, et al: Hepatitis B virus (HBV) genotype determination by the COBAS AmpliPrep/COBAS TaqMan HBV Test, v2.0 in serum and plasma matrices. J Clin Virol 45:232-236, 2009
6. Lok AS, Liang RH, Chiu EK, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study. Gastroenterology 100:182-188, 1991
7. Hui CK, Cheung WW, Zhang HY, et al: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006 (Pubitemid 44015749)
8. Fukushima N, Mizuta T, Tanaka M, et al: Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20:2013-2017, 2009